Several evidences indicate that aging negatively affects the effectiveness of influenza vaccination. Although it is well established that immunosenescence has an important role in vaccination response, the molecular pathways underlying this process are largely unknown. Given the importance of epigenetic remodeling in aging, here we analyzed the relationship between responsiveness to influenza vaccination and DNA methylation profiles in healthy subjects of different ages. Peripheral blood mononuclear cells were collected from 44 subjects (age range: 19-90 years old) immediately before influenza vaccination. Subjects were subsequently classified as responders or non-responders according to hemagglutination inhibition assay 4-6 weeks after the vaccination. Baseline whole genome DNA methylation in peripheral blood mononuclear cells was analyzed using the Illumina® Infinium 450 k microarray. Differential methylation analysis between the two groups (responders and non-responders) was performed through an analysis of variance, correcting for age, sex and batch. We identified 83 CpG sites having a nominal p-value < .001 and absolute difference in DNA methylation of at least 0.05 between the two groups. For some CpG sites, we observed age-dependent decrease or increase in methylation, which in some cases was specific for the responders and non-responders groups. Finally, we divided the cohort in two subgroups including younger (age < 50) and older (age ≥ 50) subjects and compared DNA methylation between responders and non-responders, correcting for sex and batch in each subgroup. We identified 142 differentially methylated CpG sites in the young subgroup and 305 in the old subgroup, suggesting a larger epigenetic remodeling at older ages. Interestingly, some of the differentially methylated probes mapped in genes involved in immunosenescence (CD40) and in innate immunity responses (CXCL16, ULK1, BCL11B, BTC). In conclusion, the analysis of epigenetic landscape can shed light on the biological basis of vaccine responsiveness during aging, possibly providing new appropriate biomarkers of this process.
Introduction
Influenza is an important public health challenge in our countries, with yearly epidemics responsible of significant mortality, morbidity and loss of productivity (Paules and Subbarao, 2017) . Specific populations such as very young children, individuals aged 65 years and older, or subjects with pre-existent conditions (immunocompromised states, cardiovascular or cerebrovascular diseases, diabetes, chronic respiratory failure, pregnancy) are particularly vulnerable to this infection and at greater risk for complications.
Vaccination is the most effective method to prevent influenza infection. Annual vaccination with an injectable trivalent inactivated vaccine is recommended, especially for individuals aged 65 years or older. However, the protection delivered by these vaccines is incomplete. Rates of protective immune response to vaccination are frequently low in vaccinated subjects, with worsened responses in older adults (Jefferson et al., 2010; Osterholm et al., 2012) .
Part of the poor vaccine efficacy in the elderly is due to immunosenescence (Haralambieva et al., 2015; Kennedy et al., 2016; Targonski et al., 2007) but molecular pathways associated with impaired vaccine responses remain incompletely understood. Identification of the mechanisms associated with the development of a protective immunity is of central importance in vaccinology, in order to improve our capacity to predict response to vaccination or develop potential interventions to improve the immune responses.
To date, several studies have been conducted to identify genomewide changes in transcriptional profiles that correlate with clinical response to influenza vaccination (Bucasas et al., 2011; Nakaya et al., 2011 Nakaya et al., , 2015 Obermoser et al., 2013; Thakar et al., 2015; Tsang et al., 2014; Zhu et al., 2010) , by assessing genome-wide gene expression with microarrays before and/or after vaccination of subjects. These molecular signatures, associated with better antibody responses, were frequently enriched in immune pathways, especially with type I interferon signaling, antigen presentation pathways or B-cell proliferation. Thakar et al. identified a dysregulation in this gene signature in older adults, especially in frail subjects who were non-responders to vaccination (Thakar et al., 2015) . Other large-scale profiling studies have tried to identify further relevant biomarkers that could predict vaccine response: in this attempt, Furman et al. identified nine immunological baseline predictors of protective immunity, with two of these variables involved in apoptosis (Furman et al., 2013) . Finally, models integrating and combining transcriptomic data with additional data types to predict response to vaccination have been developed recently (Tsang et al., 2014; Zimmermann et al., 2017) .
While transcriptomic data have been deeply studied in this field, few reports have been published regarding epigenetic aspects. DNA methylation has an important role in several biological processes, especially in aging (Sen et al., 2016) , and is therefore an interesting candidate to be investigated. Furthermore, DNA methylation measures tend to be more stable than transcriptomic data within the short period (days-weeks) and are more reproducible from a technical point of view. Lu et al. discovered two relevant epigenetic variations in poor-responders to the vaccine directed against Hepatitis B virus (Lu et al., 2014) . Concerning influenza vaccine, one recent study has identified numerous CpG sites showing associations with gene expression and other ones associated with the induction of the humoral immune response .
To complete these findings and evaluate the effect of age on vaccination response, here we investigated baseline (that is, immediately before vaccination) genome-wide DNA methylation in peripheral blood mononuclear cells (PBMC) from 44 healthy donors, ranging from 19 to 90 years, who received influenza vaccination and were classified as responders and non-responders according to hemagglutination inhibition assays (HIA) after 28 days.
Materials and methods

Participants
Participants (age range: 19-90 years) were recruited at the University of Miami Miller School of Medicine. Experiments were conducted using peripheral blood. Enrolled participants received the . Whole blood samples were collected immediately before vaccination. PBMC were collected using Vacutainer CPT tubes (BD 362761). Cells were washed and cryopreserved. Appropriate signed informed consent was obtained from each subject prior to enrollment. The study was approved with IRB protocol #20070481. Each participant was asked questions regarding demographics, health behaviors, presence of symptoms associated with inflammatory conditions or respiratory infections at the time of enrollment. No one reported subclinical inflammatory conditions and/or had respiratory tract infections at the time of enrollment, nor was on any anti-inflammatory treatment or on medications known to alter the immune response. Participants were excluded if they had diseases known to alter the immune response.
Assessment of response to vaccination
Immunogenicity of influenza vaccine in subjects was assessed by hemagglutination inhibition assays (HIA). For this purpose, blood samples were collected immediately before vaccination (baseline) and 4-6 weeks after to evaluate the in vivo response and identify responders and non-responders. Responders had at least a 4-fold increase in the reciprocal of the titers in response to the whole vaccine, which was the A/California Briefly, sera were pretreated with receptor destroying enzyme (RDE, Denke Seiken Co Ltd) for 20 h at 37°C; in order to inactivate this enzyme, sera were then heated at 56°C for 60 min. Two-fold serial dilutions were done; 25 μL of diluted sera were incubated with an equal volume of 4 HA units of the 2009 vaccine or of the 2010-2011 vaccine, for 1 h at room temperature and then 50 μL of a 1.25% suspension of chicken red blood cells were added. After 2 h of incubation at room temperature titers were determined.
Genome-wide DNA methylation analysis
Genome-wide DNA methylation analysis was performed on PBMC collected immediately before vaccination (baseline) and cryopreserved. DNA methylation patterns are generally stable, highly reproducible and only slightly affected by freezing (Bulla et al., 2016) . Total genomic DNA was extracted from PBMC using the AllPrep DNA/RNA Mini kit (Qiagen), according to manufacturer's instructions. DNA concentrations were determined using NanoDrop spectrophotometer. DNA was bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research Corporation®) and analyzed on the Infinium HumanMethylation450 BeadChip (Illumina®) following manufacturer's instructions (Bibikova et al., 2011) . Arrays were scanned by HiScan (Illumina®) and signal intensities were extracted from .idat files using the minfi Bioconductor package (Aryee et al., 2014) . Data were normalized using the preprocess Quantile function of the package minfi. Probes on the X and Y chromosomes were removed, as well as probes associated to a SNP. Identification of CpG sites with differential methylation between responders and non-responders to influenza vaccination was performed through an analysis of variance (ANOVA) model, correcting for sex and batch. CpG sites differentially methylated between responders and nonresponders were defined as having a nominal p-value inferior to 0.01 and an absolute difference between values of responders and non-responders of at least 0.05. Figures were generated using R.
Epigenetic age estimation
DNAm age, also referred to as epigenetic age, was calculated as described by Horvath (Horvath, 2013) , using the online age calculator freely available at the website: https://dnamage.genetics.ucla.edu.
Results
DNA methylation differences in responders and non-responders to influenza vaccination
Forty-four subjects were included in the present study: 23 were responders to influenza vaccine, while 21 were considered as non-responders according to HIA assay. Characteristics of the subjects are summarized in Table 1 .
We used the Illumina® Infinium 450 k microarray to generate genome wide DNA methylation data from PBMC collected pre-vaccination (baseline). As a first step in our analysis, we compared DNA methylation between responders and non-responders to influenza vaccination by ANOVA, correcting for age, sex and batch. No CpG sites withstood Benjamini-Hochberg false discovery rate correction for multiple testing (significant threshold: q-value < 0.05). We then considered less stringent criteria (uncorrected p-value inferior to 0.01 and absolute difference between mean methylation values of responders and non-responders of at least 0.05). In this way, we identified 83 differentially methylated CpG sites between the two groups of subjects, mapping in 52 annotated genes (Tables 2 and 3 ; Supplementary File 1), that were able to distinguish responders and non-responders in a multidimensional scaling (MDS) plot (Fig. 1A) . When looking at the genomic localization of these probes, we found 3 genomic regions in which multiple adjacent CpG probes showed differential methylation between responders and non-responders: 3 probes mapped within the chr1:57110663-57111337 island associated to PRKAA2 gene (Fig. 1B) , 2 mapped within the chr6:160209941-160212015 island associated to TCP1/MRPL18 genes and 2 mapped in TRAPPC9 gene, one in the chr8:141348840-141349195 island and one in the shore of the chr8:141467218-141467927 island. The presence of multiple differentially methylated probes within the same region indicates a general epigenetic remodeling of the genomic tract, which is likely to be biologically relevant (Bacalini et al., 2015; Wessely and Emes, 2012) .
Age-associated epigenetic determinants of vaccination response
In order to assess the effect of age on vaccination response, for each of the CpG probes identified as differentially methylated in the previous analysis we calculated the association with age, considering separately responders and non-responders to influenza vaccine ( Supplementary   Files 1 and 2 ). For some CpG probes, such as cg14987745 in TDG gene, methylation differences between responders and non-responders were not affected by age (Fig. 2A) . On the contrary, others CpG sites showed age-association specifically in one of the two groups. For example, the probe cg26923084 in the gene NID2 showed an age-dependent decrease in methylation only in non-responders, with larger DNA methylation differences after the age of 50 years old (Fig. 2B) .
To better identify the epigenetic determinants of vaccine responsiveness that are dependent on the age of the subjects, we divided the cohort in two groups including younger (age < 50) and older (age ≥ 50) subjects. Within each subgroup, we compared DNA methylation between responders and non-responders, correcting for sex and batch. Also in this case, no CpG site survived the multiple test correction. Using the same selection criteria described above, in the Young group we identified 142 differentially methylated CpG sites, mapping in 98 annotated genes (Tables 2 and 4 ; Supplementary Files 3 and 4). Four loci had multiple differentially methylated probes: C5orf33 (2 CpG probes in the chr5:36241003-36242664 island), HCG4P6 (3 CpG probes in the chr6:29894140-29895117 island and its shore), TRAF3 (2 CpG probes in the body of the gene) and RPTOR (4 CpG probes in the body of the gene, in the chr17:78863569-78863813 island and in the adjacent shore). In the Old subgroup, 305 CpG probes turned out to be differentially methylated, mapping in 206 genes (Tables 2 and  5 ; Supplementary Files 3 and 5). Eight loci contained multiple differentially methylated probes between old responders and non-responders: KIF5C (2 CpG probes, one in the chr2:149632682-149633882 island and one in the shore of chr2:149645536-149645834 island), COL7A1 (2 CpG probes in the chr3:48631882-48632901 island), MIR886 (2 CpG probes in the chr3:48631882-48632901 island), TRAPPC9 (2 CpG probes, one in the chr8:141348840-141349195 island and one in the shore of chr8:141467218-141467927 island), NKX2-3 (2 CpG probes in the chr10:101294443-101297263 island), MCF2L (2 CpG probes, one in the chr13:113687421-113687828 island and one in the shore of the chr13:113714784-113715160 island), MYOD (2 CpG probes, one in the shore of chr17:30822917-30823210 island and one in the chr17:30845903-30846702 island) and RGL3 (2 CpG probes, one in the chr19:11531278-11531590 island and one in its shore). No CpG probes were identified as differentially methylated both in the Young and in the Old group; however, when considering the genes in which the CpG probes map, COL7A1 and PAPLN turned out to be present in both the comparisons. For both the genes, the CpG probes identified as differentially methylated in the two comparisons mapped in near positions along the chromosome (within 1000 bp) and showed consistent age-dependent trends (for both the genes, and age-related hypomethylation specifically in the non-responders group), suggesting a general epigenetic remodeling of the two genomic regions.
Finally, we investigated if the responsiveness to vaccination was associated to the epigenetic age of the subjects. In the last few years, DNA methylation-based biomarkers have gained particular relevance in the field of aging research and have been proposed as proxy of the biological age of an individual. The most popular epigenetic age estimator is Horvath's epigenetic clock (Horvath, 2013) which has been shown to correlate with mortality (Chen et al., 2016; Christiansen et al., 2016; Marioni et al., 2015a; Perna et al., 2016) , physical and cognitive fitness (Marioni et al., 2015b) and to detect a biological age-acceleration in frail subjects (Breitling et al., 2016) . Frailty is of particular importance from our perspective, since it has been observed that this status impacts susceptibility to influenza and responsiveness to Number of differentially methylated CpG sites between responders and non-responders to influenza vaccination, identified according to criteria described in Methods.
Number of differentially methylated CpG sites between responders and non-responders
All subjects 83 Young subjects (age < 50 years)
142
Old subjects (age ≥ 50 years) 305 influenza vaccine (Yao et al., 2011 ). Here we used Horvath's epigenetic clock to estimate the DNA methylation age (DNAmAge) in our cohort. Then for each individual, we calculated the delta between chronological age and DNAmAge, in order to detect deceleration (the subject is epigenetically younger than his/her chronological age) or acceleration effects (the subject is epigenetically older than his/her chronological age). No significant differences in delta values were observed between responders and non-responders, nor when we divided the cohort in the young and old subgroups (Fig. 3 ).
Discussion
Understanding mechanisms associated with impaired vaccine responses is an important goal and this is particularly true in the context of aging. Age-associated alterations in immune responses, named immunosenescence, are in part responsible of the poor response after vaccination in elderly (Goronzy and Weyand, 2013) . Role of DNA methylation in this phenomenon has been investigated in subjects aged 50-74 years old vaccinated against influenza. The authors identified multiples CpG sites associated with age and with strong correlations with immunosenescence markers , highlighting the possible implication of epigenetic regulation as an active mechanism that shapes the immune response during aging.
In this study, we analyzed baseline whole genome DNA methylation profiles of 44 subjects ranging 19-90 years and receiving influenza vaccination. To the best of our knowledge, this is the first study to investigate methylation data in vaccinated subjects with such a wide range of ages, making it possible to identify age-related determinants of influenza vaccination response. Accordingly, we identified 83 differentially methylated probes when correcting for the age of the subjects, 142 in the young subgroup and 305 in the old subgroup. This suggests that DNA methylation differences between responders and non-responders are larger at older ages compared to younger ones. Nonresponders did not show epigenetic age acceleration effects compared to responders, according to Horvath's epigenetic clock.
To our knowledge, none of the CpG sites we identified was previously found differentially methylated in studies investigating DNA methylation profiles in human vaccinology, and no significant enrichment in KEGG pathways was observed (data not shown). However, it is interesting that we identified differentially methylated probes mapping in genes that are involved in immunosenescence (CD40) (Metcalf et al., 2015; Toapanta and Ross, 2009 ) and in innate immunity responses during viral infection: CXCL16 (Piqueras et al., 2006) , ULK1 (Prantner et al., 2017) , BCL11B (Yu et al., 2015) , BTC (Al-Yahya et al., 2015) .
Senescence of the adaptive compartment of immunity, which is involved in the classic immunological memory (Crotty and Ahmed, 2004) , has been widely studied and most of the cellular markers studied in the report published by Kennedy et al. are related to B or T lymphocytes . However, during last years, evidence has emerged that also innate immune cells have a sort of memory, called "trained immunity". This phenomenon could be a contributor to the protective effects of vaccination, independently of T and B cells, mostly observed in bacteriological vaccines, such as BCG (Garly et al., 2003; Kleinnijenhuis et al., 2012; Tribouley et al., 1978; van't Wout et al., 1992) . Whereas immunological memory associated to adaptive immunity relies upon genetic recombination and mutations for the development of antigen specific receptors, mechanistic studies have brought evidence that trained immunity does not involve these types of permanent genetic changes but is largely based on epigenetic remodeling in innate immune cells (such as myeloid cells (monocytes, macrophages), natural killer cells or innate lymphoid cells) . The epigenetic shift, mostly based on histone modifications but also on microRNAs and DNA methylation changes, follows modifications in cellular metabolism driven by the antigenic stimulation (Arts et al., 2016) and can shape the cellular response and remains over time. Identification of differentially methylated CpG sites between responders and non-responders after vaccination is an important step to gain knowledge on these processes, for the identification of genes that could be potential targets for functional analysis and for the development of new strategies of vaccination.
In this study we analyzed total PBMC samples, like in most published system vaccinology studies which used whole blood or PBMC. One important advantage of this approach is that blood and PBMC can be easily obtained from individuals, but an important limit is the presence multiple diverse cell subsets. Indeed, the heterogeneity in cell populations in the analysis can possibly hide differences in DNA methylation patterns in individual cell types. Hoek et al. previously investigated the transcriptomic and proteomic profiles from PBMC and from sorted immune cells after influenza vaccination (T cells, B cells, natural killer cells, myeloid dendritic cells, monocytes and neutrophils). They described significantly different RNA and protein expression profiles between the groups (Hoek et al., 2015) .
Another possible limitation in our work is the lack of data regarding pre-existing immune status of the subjects that could affect vaccine response. It is known that older subjects are frequently non-responders to vaccine and that a 4-fold increase in HIA titers is more frequently found in young subjects as compared to old ones: in a meta-analysis, Goodwin et al. generated an adjusted odds-ratio of responses in elderly vs young adults of 0.24 to 0.59 in terms of seroconversion and seroprotection against 3 different influenza antigens (H1N1, H3N2 and B) (Goodwin et al., 2006) . Weakened serological response to vaccination in elderly subjects are related to the effect of immunosenescence, but previous exposures to influenza antigens (via vaccinations or infections) have also an influence on the response to the new vaccination. In general, subjects with repeated previous influenza vaccinations and influenza specific antibodies at baseline have a reduced humoral response and so lower post-vaccination titers (Bucasas et al., 2011; Gulati et al., 2005; Huang et al., 2017; Ng et al., 2013; Sasaki et al., 2008; Thakar et al., 2015; Tsang et al., 2014) . However, it has also recently been demonstrated in a study conducted on 136 young and 122 elderly individuals that young individuals respond better than elderly individuals to the first vaccination, but after subsequent vaccinations the difference in response between young and elderly individuals declines rapidly, suggesting that different prior vaccination history and/or infection histories must also be taken in consideration when influenza vaccination is examined (Mosterín Höpping et al., 2016) .
In this study, we evaluated the association of baseline DNA methylation patterns and response to the vaccination at different ages. Future studies should systematically evaluate the epigenetic response to influenza vaccination in subjects of different ages, analyzing DNA methylation and gene expression at different time points post-vaccination and correlating changes in epigenetic patterns with the antibody response. Although it has been demonstrated that vaccination does not profoundly alter DNA methylation profiles in PBMC , further studies are necessary in this field, considering the impact of the age of the individuals and analyzing different cell types separately. Furthermore, DNA methylation signatures should be explored and validated in other independent datasets considering other influenza strains.
Conclusion
In conclusion, in this paper we identified possible age-related DNA methylation contributors to vaccine responsiveness. Further studies on larger independent cohorts are needed to define epigenetic biomarkers that can predict the vaccine efficacy. These models could be used to develop novel strategies to achieve optimal protective immune responses, especially in the elderly.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.exger.2018.01.019.
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